-- Scott Roberts
FRIDAY, April 27 (HealthDay News) -- Votrient (pazopanib) has
been approved by the U.S. Food and Drug Administration to treat
people with soft tissue sarcoma that have received previous
This type of tumor originates in soft tissue such as a muscle,
fat, or fibrous tissue, the agency said in a news release. About
10,000 cases of soft tissue sarcoma are reported each year in the
Votrient works by inhibiting angiogenisis, the production of new
blood vessels that fuel tumor growth. The drug's safety and
effectiveness were evaluated in clinical studies involving 369
people with soft tissue sarcoma who had undergone chemotherapy.
Among people who took Votrient, the disease didn't progress for an
average of 4.6 months, compared to 1.6 months among people who took
an inactive placebo.
The most common side effects of Votrient included fatigue,
diarrhea, nausea, weight loss, high blood pressure and decreased
appetite. The drug's label will carry a "black box" warning of the
potential for severe liver damage, which could be fatal. People who
are given the drug should have their liver function monitored, the
Votrient was first approved in October 2009 to treat advanced
kidney cancer. The drug is marketed by GlaxoSmithKline, based in
Research Triangle Park, N.C.
Medline Plus has more about this drug.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.